BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37906431)

  • 21. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
    Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
    Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
    Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.
    Asghari A; Wall K; Gill M; Vecchio ND; Allahbakhsh F; Wu J; Deng N; Zheng WJ; Wu H; Umetani M; Maroufy V
    Oncotarget; 2022; 13():600-613. PubMed ID: 35401937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
    Soosainathan A; Iravani M; El-Botty R; Alexander J; Sourd L; Morisset L; Painsec P; Orha R; Nikitorowicz-Buniak J; Pancholi S; Haider S; Dowsett M; Marangoni E; Martin LA; Isacke CM
    Cancer Res; 2024 Jan; 84(1):17-25. PubMed ID: 37801608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
    Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment.
    Malavasi E; Giamas G; Gagliano T
    Cancer Gene Ther; 2023 Jul; 30(7):932-935. PubMed ID: 37085602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1.
    Ruidas B; Sur TK; Das Mukhopadhyay C; Sinha K; Som Chaudhury S; Sharma P; Bhowmick S; Majumder R; Saha A
    Breast Cancer; 2022 Jul; 29(4):748-760. PubMed ID: 35511410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.
    Kurebayashi J
    Breast Cancer; 2003; 10(2):112-9. PubMed ID: 12736563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.
    Ward E; Varešlija D; Charmsaz S; Fagan A; Browne AL; Cosgrove N; Cocchiglia S; Purcell SP; Hudson L; Das S; O'Connor D; O'Halloran PJ; Sims AH; Hill AD; Young LS
    Clin Cancer Res; 2018 Aug; 24(15):3692-3703. PubMed ID: 29567811
    [No Abstract]   [Full Text] [Related]  

  • 33. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer.
    Murthy D; Dutta D; Attri KS; Samanta T; Yang S; Jung KH; Latario SG; Putluri V; Huang S; Putluri N; Park JH; Kaipparettu BA
    Cancer Lett; 2024 Apr; 587():216724. PubMed ID: 38373689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
    Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
    PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of ER-Src axis in hormonal therapy resistance.
    Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
    Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
    Lanceta L; Lypova N; O'Neill C; Li X; Rouchka E; Chesney J; Imbert-Fernandez Y
    Breast Cancer Res Treat; 2021 Apr; 186(3):677-686. PubMed ID: 33599863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.
    Semina SE; Pal P; Kansara NS; Huggins RJ; Alarid ET; Greene GL; Frasor J
    Breast Cancer Res; 2022 Mar; 24(1):19. PubMed ID: 35264224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oestrogen receptor negativity in breast cancer: a cause or consequence?
    Gajulapalli VNR; Malisetty VL; Chitta SK; Manavathi B
    Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27884978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
    Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
    Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.